Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres

Cell Cycle

Volumn 11, Issue 22, 2012, Pages 4242-4251

  Borgna, Silvia ^a   Armellin, Michela ^a   Di Gennaro, Alessandra ^a   Maestro, Roberta ^a   Santarosa, Manuela ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Breast cancer; Cancer stem cells; Cell lines; Epithelial to mesenchymal transition; Mammospheres

Indexed keywords

CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; IN VITRO STUDY; MAMMOSPHERE; MESENCHYMAL STEM CELL; PHENOTYPE; UPREGULATION;

EID: 84869387339     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22543     Document Type: Article

References (47)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098.
3. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15(Suppl 5):39-48; PMID:21138954; http://dx.doi.org/10.1634/ theoncologist.2010-S5-39.
4. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68; PMID:20813035; http://dx.doi.org/10.1186/bcr2635.
5. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26:2373-8; PMID:18413639; http://dx.doi.org/10.1200/JCO.2007.14.4287.
6. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10:R53; PMID:18559090; http://dx.doi.org/10.1186/bcr2108.
7. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16:876-87; PMID:20103682; http://dx.doi.org/10.1158/1078-0432.CCR-09-1532.
8. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17:1253-70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803.
9. Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, Kaba M, et al. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res 2007; 67:8131-8; PMID:17804725; http://dx.doi.org/10.1158/0008-5472.CAN-06-4493.
10. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 2008; 10:R52; PMID:18541018; http://dx.doi.org/10.1186/bcr2106.
11. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138:1083-95; PMID:19766563; http://dx.doi.org/10. 1016/j.cell.2009.06.048.
12. Eguiara A, Holgado O, Beloqui I, Abalde L, Sanchez Y, Callol C, et al. Xenografts in zebrafish embryos as a rapid functional assay for breast cancer stemlike cell identification. Cell Cycle 2011; 10:3751-7; PMID:22033190; http://dx.doi.org/10.4161/cc.10.21.17921.
13. Hu X, Ghisolfi L, Keates AC, Zhang J, Xiang S, Lee DK, et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle 2012; 11:2691-8; PMID:22732500; http://dx.doi.org/10.4161/cc.21021.
14. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507; PMID:18443585; http://dx.doi.org/10.1038/ng.127.
15. Wong DJ, Segal E, Chang HY. Stemness, cancer and cancer stem cells. Cell Cycle 2008; 7:3622-4; PMID:19029796; http://dx.doi.org/10.4161/cc.7.23.7104.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas. 0530291100.
17. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98:1777-85; PMID:17179479; http://dx.doi.org/10.1093/jnci/djj495.
18. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010; 102:1637-52; PMID:20935265; http://dx.doi.org/10.1093/jnci/djq361.
19. Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) 2010; 2:735-41; PMID:20975209.
20. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420- 8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104.
21. Browne G, Sayan AE, Tulchinsky E. ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle 2010; 9:886-91; PMID:20160487; http://dx.doi.org/10.4161/cc.9.5.10839.
22. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5:744-9; PMID:16148886; http://dx.doi.org/10.1038/nrc1694.
23. Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 2011; 129:2310-4; PMID:21792896; http://dx.doi.org/10.1002/ijc.26311.
24. Ansieau S. EMT in breast cancer stem cell generation. [Epub ahead of print]. Cancer Lett 2012; PMID:22634497; http://dx.doi.org/10.1016/j.canlet. 2012.05.014.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.org/10.1016/j.stem.2007.08.014.
26. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-13; PMID:19190339; http://dx.doi.org/10.1158/0008-5472.CAN-08-2741.
27. Gasparotto D, Polesel J, Marzotto A, Colladel R, Piccinin S, Modena P, et al. Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget 2011; 2:1165-75; PMID:22201613.
28. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008; 7:3112-8; PMID:18927505; http://dx.doi.org/10.4161/cc.7.20.6851.
29. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/) CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:235- 52; PMID:20521089; http://dx.doi.org/10.1007/ s10911-010-9175-z.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03. 027.
31. Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, et al. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010; 28:1081-8; PMID:20506111; http://dx.doi.org/10.1002/stem.435.
32. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2012; 109:2772-7; PMID:21940501; http://dx.doi.org/10.1073/pnas.1017626108.
33. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13:R118; PMID:22112299; http://dx.doi.org/10.1186/bcr3061.
34. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64:937-46; PMID:21680574; http://dx.doi.org/10.1136/jcp.2011.090456.
35. Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, et al. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol 2012; 25:388-97; PMID:22080062; http://dx.doi.org/10.1038/modpathol.2011.172.
36. Eirew P, Kannan N, Knapp DJ, Vaillant F, Emerman JT, Lindeman GJ, et al. Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells. Stem Cells 2012; 30:344-8; PMID:22131125; http://dx.doi.org/10. 1002/stem.1001.
37. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29:32-45; PMID:21280157; http://dx.doi.org/10.1002/stem.563.
38. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011; 10:1378-84; PMID:21552008; http://dx.doi.org/10.4161/cc.10.9.15486.
39. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 2012; 109:2742-7; PMID:21969591; http://dx.doi.org/10.1073/pnas.1106509108.
40. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1:84-96; PMID:18516279; http://dx.doi.org/10.1016/j.molonc.2007.02.004.
41. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ 2011; 18:1470-7; PMID:21617693; http://dx.doi.org/10. 1038/cdd.2011.60.
42. Viloria-Petit AM, Wrana JL. The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle 2010; 9:623-4; PMID:20107326; http://dx.doi.org/10.4161/cc.9.4.10779.
43. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 2012; 132:75-85; PMID:21553120; http://dx.doi.org/10.1007/s10549-011-1534-y.
44. Santarosa M, Maestro R. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Cancer Metastasis Rev 2012; 31:131-42; PMID:22101651; http://dx.doi.org/10.1007/s10555-011-9336-6.
45. Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P, et al. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 2010; 9:2878-87; PMID:20581442; http://dx.doi.org/10.4161/cc.9.14.12371.
46. Eckert MA, Yang J. Targeting invadopodia to block breast cancer metastasis. Oncotarget 2011; 2:562-8; PMID:21725138.
47. Hurteau GJ, Spivack SD. mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. Anal Biochem 2002; 307:304-15; PMID:12202248; http://dx.doi.org/10.1016/S0003-2697(02)00058-1.